| Abbey Lynne Rouleau, NP | |
|
Cvmc Palliative Care, 130 Fisher Road 2nd Floor, Berlin, VT 05602 | |
| (802) 371-5372 | |
| Not Available |
| Full Name | Abbey Lynne Rouleau |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | Cvmc Palliative Care, Berlin, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265086037 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 101.0134379 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Vermont Medical Center Inc | 9335138817 | 204 |
News Archive
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
A near miss, like any error, is an opportunity to examine how mistakes are made and what changes might prevent them. Yet we have no idea how many near misses there are. Many experts feel that near-miss errors dwarf the number of known errors, a number that is already too high for comfort. (According to a 2006 report, medication errors alone injure an estimated 1.5 million patients a year.) But the instinct for most medical professionals is to keep these shameful mistakes to ourselves (Danielle Ofri, 5/28).
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community pharmacies, and the urgent need for better enforcement of laws.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
› Verified 3 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
A near miss, like any error, is an opportunity to examine how mistakes are made and what changes might prevent them. Yet we have no idea how many near misses there are. Many experts feel that near-miss errors dwarf the number of known errors, a number that is already too high for comfort. (According to a 2006 report, medication errors alone injure an estimated 1.5 million patients a year.) But the instinct for most medical professionals is to keep these shameful mistakes to ourselves (Danielle Ofri, 5/28).
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community pharmacies, and the urgent need for better enforcement of laws.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
› Verified 3 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023028784 PECOS PAC ID: 9335138817 Enrollment ID: O20051220000393 |
News Archive
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
A near miss, like any error, is an opportunity to examine how mistakes are made and what changes might prevent them. Yet we have no idea how many near misses there are. Many experts feel that near-miss errors dwarf the number of known errors, a number that is already too high for comfort. (According to a 2006 report, medication errors alone injure an estimated 1.5 million patients a year.) But the instinct for most medical professionals is to keep these shameful mistakes to ourselves (Danielle Ofri, 5/28).
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community pharmacies, and the urgent need for better enforcement of laws.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Abbey Lynne Rouleau, NP Cvmc Palliative Care, 130 Fisher Road 2nd Floor, Berlin, VT 05602 Ph: (802) 371-5372 | Abbey Lynne Rouleau, NP Cvmc Palliative Care, 130 Fisher Road 2nd Floor, Berlin, VT 05602 Ph: (802) 371-5372 |
News Archive
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).
As reported in a March 18, New York Times editorial, "Honest Food Labels," FDA Commissioner, Margaret Hamburg, M.D., publicized letters to 17 food companies accusing them of - "masking undesirable ingredients" - in their products. She also emphasized the importance of "providing nutrition information that consumers can rely on."
A near miss, like any error, is an opportunity to examine how mistakes are made and what changes might prevent them. Yet we have no idea how many near misses there are. Many experts feel that near-miss errors dwarf the number of known errors, a number that is already too high for comfort. (According to a 2006 report, medication errors alone injure an estimated 1.5 million patients a year.) But the instinct for most medical professionals is to keep these shameful mistakes to ourselves (Danielle Ofri, 5/28).
With increased use of antibiotics worldwide linked to growing antibiotic resistance, a world-first study co-authored by a QUT researcher has highlighted the growing impact of non-prescription supply of antibiotics in community pharmacies, and the urgent need for better enforcement of laws.
Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.
› Verified 3 days ago
Ms. Quincy Campbell, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1311 Barre-montpelier Rd, Berlin, VT 05602 Phone: 802-371-4239 Fax: 802-371-4237 | |
Christina Marie Tourangeau, APRN, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1311 Barre-montpelier Road, Suite 200, Berlin, VT 05602 Phone: 802-371-4239 Fax: 802-371-4237 | |
David Alexander Segel, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-225-7000 | |
Karen Gibbs, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 142 Woodridge Rd, Berlin, VT 05602 Phone: 802-371-4700 | |
Margaret Jones, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 130 Fisher Rd, Berlin, VT 05602 Phone: 802-471-2100 | |
Morgan Lamson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Central Vermont Medical Center, 130 Fisher Road, Berlin, VT 05602 Phone: 802-371-4700 Fax: 802-371-4720 |